BIOCON — Biocon Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Biocon, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Interim Report	ARS	ARS	ARS	PRESS
Standards:	—	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	71,431	81,840	111,742	147,557	152,617
Cost of Revenue
Gross Profit	44,913	49,785	68,238	92,712	100,642
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	60,258	70,795	96,225	128,786	136,859
Operating Profit	11,173	11,045	15,517	18,771	15,758
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10,677	9,831	8,971	15,252	18,866
Provision for Income Taxes
Net Income After Taxes	8,462	7,716	6,430	12,978	14,294
Minority Interest
Net Income Before Extraordinary Items
Net Income	7,405	6,484	4,627	10,225	10,133
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,405	6,484	4,627	10,225	10,133
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	5.1	5.97	4.35	7.89	7.85
Dividends per Share